Safety Profile: Adverse Events and Treatment Modifications in MARIPOSA-2

The MARIPOSA trial revealed promising survival benefits with amivantamab plus lazertinib vs osimertinib for patients with EGFR-mutant lung cancer.

Stephen Liu, MD; and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

AI transforms non-small cell lung cancer management, enhancing diagnostics, treatment predictions, and personalized care strategies for improved patient outcomes.

Experts from Washington University in St Louis discuss dosing considerations and toxicity management strategies for TROP2-targeted ADCs in NSCLC.

The decision is supported by results from the phase 2 TROPION-Lung05 and phase 3 TROPION-Lung01 trials.

Data from the phase 3 GEMSTONE-302 trial support sugemalimab plus chemotherapy as a frontline treatment option in metastatic non–small cell lung cancer.